ChinaDaily Briefs

Daily Brief China: Anta Sports Products, Horizon Robotics, Beijing Tiantan Biological Products, Fosun Tourism, Meituan and more

In today’s briefing:

  • Anta/Li Ning/Xtep:  China Sportswear 1Q24 Update
  • Horizon Robotics Pre-IPO – The Positives – Rapid Revenue Growth
  • Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China’s Blood Products Industry
  • Horizon Robotics Pre-IPO – The Negatives – Large Part of the Growth Stems from Its JV
  • Fosun Tourism (1992 HK): A Long-Awaited Upturn
  • Meituan (3690 HK): Lack of Clear Topline Driver Remains a Concern


Anta/Li Ning/Xtep:  China Sportswear 1Q24 Update

By Steve Zhou, CFA

  • Anta Sports Products (2020 HK), Li Ning (2331 HK), and Xtep International (1368 HK) have announced 1Q24 operational updates, with additional color given in post conference calls. 
  • Anta: Retail sales started to accelerate in mid-March, and March were better than January and February. 
  • Li Ning:  offline retail sales down low-single-digit in 1Q24, driven by wholesale down mid-single-digit, while retail grew mid-single-digit.  E-commerce grew 20-30% yoy.  

Horizon Robotics Pre-IPO – The Positives – Rapid Revenue Growth

By Sumeet Singh

  • Horizon Robotics is looking to raise US$500m in its upcoming Hong Kong IPO. The bookrunners on the deal are GS, MS and China Securities.
  • Horizon Robotics (HR) is a provider of advanced driver assistance systems (ADAS) and autonomous driving (AD) solutions for passenger vehicles, empowered by its proprietary software and hardware technologies.
  • In this note, we talk about the positive aspects of the deal.

Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China’s Blood Products Industry

By Xinyao (Criss) Wang

  • Guangming District State-owned Assets Supervision and Administration Bureau reached a cooperation agreement with China National Biotec to establish a joint venture, which will become the new controlling shareholder of Weiguang.
  • Since Tiantan is already Sinopharm’s subsidiary, there will be horizontal competition issue in the field of blood product business between Tiantan and Weiguang, mainly due to significant business overlap.
  • Some spin-offs and integrations are expected between Tiantan and Weiguang. As the reform of SOE enters a new stage, the two companies could end up very different.

Horizon Robotics Pre-IPO – The Negatives – Large Part of the Growth Stems from Its JV

By Sumeet Singh

  • Horizon Robotics is looking to raise US$500m in its upcoming Hong Kong IPO. The bookrunners on the deal are GS, MS and China Securities.
  • Horizon Robotics (HR) is a provider of advanced driver assistance systems (ADAS) and autonomous driving (AD) solutions for passenger vehicles, empowered by its proprietary software and hardware technologies.
  • In this note, we talk about the not-so-positive aspects of the deal.

Fosun Tourism (1992 HK): A Long-Awaited Upturn

By Osbert Tang, CFA

  • Fosun Tourism (1992 HK) saw a healthy 15.8% overall business volume growth in 1Q24, with net profit sustaining improvement. This should justify a catch-up in share price.
  • The cumulative bookings for Club Med for 1H24 have increased 13% YoY, while those for 2H24 have increased 10%. Positive forward bookings indicate an encouraging outlook.
  • Four new Club Med resorts to be opened in 2024 and the increase in attractiveness of Hainan after it turns into a duty-free island by 2025 are both drivers.   

Meituan (3690 HK): Lack of Clear Topline Driver Remains a Concern

By Eric Chen

  • Meituan has navigated through its most challenging period since IPO as competition moderates and reorg comes close to completion. 
  • 1Q results should kick off an upward earnings cycle through to the end of 2024 when the company’s efforts to revamp loss-making new initiative businesses gather pace. 
  • That said, lack of clear topline driver remains the key reason for our cautious view about the sustainability of re-rating. Maintain neutral.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars